Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison

Recruiting now

Conditions studied: Brain Neoplasms

In brief

This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.

Key facts

Study ID

NCT07272616

Run by

Region Stockholm

People needed

100

Starts

2026-01-28

Expected to finish

2027-12-31

Last updated by the study team

2026-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Scheduled for clinical brain MRI with gadolinium contrast
• Known or suspected brain metastases
• Able to provide informed consent
• Able to lie still for the duration of the MRI examination

You may not qualify if…

• Contraindications to MRI
• Known allergy or contraindication to gadolinium-based contrast agents
• Renal impairment (eGFR < 30 mL/min/1.73m²)
• Pregnant or breastfeeding
• Inability to comply with study procedures

Where it is running

• Karolinska University Hospital — Stockholm, Solna, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.